

Corporate Presentation

Penser Market, May 25, 2023

Erik Kinnman, M.D., PhD, MBA
CEO



Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Vivesto has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Oncology focused R&D company




- Track record of bringing a product to the market and commercial production
 - Cost effective organization
- New focus on developing drugs from preclinical stage to clinical PoC
 - Deliver opportunities in existing portfolio and XR technology platform
 - Expand portfolio
- Nasdaq Stockholm mid cap: [vive.st](https://www.vivesto.se)
 - MCAP 190 MSEK
 - Cash 119 MSEK Q1 2023

Our current portfolio

Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration/ approval	Commercial launch	Geography
Apealea (paclitaxel micellar)	Ovarian cancer							EU/EEA
Apealea (paclitaxel micellar)	Ovarian cancer							USA
Cantrixil IP	Ovarian cancer							Global
Docetaxel micellar	Prostate cancer							EU/EEA
Cantrixil	Other forms of cancer							Global




Portfolio and technology platform activities




Small molecules

- **Apealea launch**
 - Vivesto and Elevar seek to transfer Apealea rights to a third party
 - In parallel seek a partner for China
- **Paccal vet**
 - FDA pre submission conference underway
 - Clinical trial initiation planned for H2 2023
- **Docetaxel micellar**
 - Clinical study completed end 2023, results 2024
- **Cantrixil**
 - Production clinical trial material
 - Alternative indications investigated: bladder and hematological cancer
- **XR drug delivery platform progress**



Solubilization technologies
(XR-17™/XR-18)

XR-17™/XR-18 - solubilization technology to improve safety & efficacy



- ✓ High drug delivery capability
- ✓ Shorter infusion time^{1,2}
- ✓ Superior solubility
- ✓ Enhanced API bioavailability
- ✓ Validated safety in cancer¹
- ✗ No or limited need for pre-medication¹
- ✗ No alcohol, Crem. EL, Polys.80, human albumin

Potential cancers

- ✓ Ovarian
- ✓ Prostate
- ✓ Bladder
- ✓ Lung
- ✓ Breast

1) Apealea Summary of Product Characteristics. www.ema.europa.eu



2) Paclitaxel 6 mg/ml Summary of Product Characteristics. <https://products.mhra.gov.uk>

Apealea®



 Vivesto

Apealea[®] - commercial launch initiated



Global agreement with Elevar Therapeutics, worth up to 698 MUSD + royalties (incl. 20 MUSD upfront)

Worldwide ovarian cancer peak sales estimates ~280MUSD

Paccal vet



Low risk opportunity to rapidly develop significant value in area of high unmet medical need





- **Paccal Vet = paclitaxel micellar (XR-17™)**
 - Paclitaxel is an effective cancer treatment not available for animals
 - XR-17 allows for efficient and safe delivery also in animals
 - Manufacturing process in place since Paccal Vet is identical to Apealea
 - Short time to market
- **Compelling market opportunity**
 - 90 million pet dogs in the US and 93 million in Europe
 - Global companion animal health market 17 BUSD 2021, CAGR of 6%
- **Indication seeking study planned H2 2023**
- **Partnering opportunity**

Oncology pipeline and XR platform



Cantrixil – new mechanism of action





- Small molecule with several targets and therapeutic opportunities:
 - Tubulin-binding potent cytotoxicity against CD44+ and potential to overcome drug resistance¹
 - Decreases ERK1/2 phosphorylation lowering cell proliferation²
 - Increases c-Jun phosphorylation resulting in apoptosis²
 - Impacts mitochondrial metabolic reprogramming via OXPHOS inhibition^{3,4}
- In clinical development for the treatment of late-stage ovarian cancer
 - Study drug supply underway
- Opportunity to expand indication area to bladder cancer and blood cancer

¹ McLoughlin et al, *Pharmaceuticals*, 2020, 13, 8. ² Saif et al., *Cancer Chemother. Pharmacol.*, 2017, 79(2), 303.

³ Sica et al., *Int. J. Cancer*, 2020, 146(1), 10. ⁴ Jagust et al., *Front. Pharmacol.*, 2019, 10.

Docetaxel micellar – Phase IB ongoing

- **Docetaxel micellar i.v.**
 - Standard of care for advanced prostate cancer, approved for many solid malignancies
 - XR-17™ to enable administration without solubility enhancers
- **Open-label trial phase IB**
 - Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
 - Maximum tolerated dose
- **12/18 recruited**
- **Study recruitment completion expected end 2023**



Near-term focus & activities

- Runway extension until H2 2024
- Cantrixil preclinical data Q3 2023
- Paccal vet FDA feed back Q3 2023
 - Clinical trial initiation H2 2023
- Docetaxel micellar clinical study completion Q4 2023
 - Results Q1 2024
- XR-18 platform data H2 2023
- New licensee Apealea



Thanks

Vivesto AB (STO: VIVE)
Gustav III:s Boulevard 46,
5th floor
169 73 Solna,
Sweden

 +46 018-50 54 40

 IR@vivesto.com

 www.vivesto.com

 www.linkedin.com/company/vivesto-ab

 www.twitter.com/vivesto



20 main shareholders

#	Ägare	VIVE	Kapital
1	Per Arwidsson med närstående	133645485	24,84%
2	Avanza Pension	30560218	5,68%
3	Ilija Batljan	9838665	1,83%
4	Swedbank Försäkring	8047908	1,50%
5	Johan Zetterstedt	8000000	1,49%
6	Nordnet Pensionsförsäkring	6626143	1,23%
7	Mastan AB (Håkan Lagerberg)	6209851	1,15%
8	Jerry Wiström	4659456	0,87%
9	Philip Du Rietz	4646200	0,86%
10	Christer Ericson	3866289	0,72%
11	Thoren Tillväxt AB	3389159	0,63%
12	SEB Fonder	3133601	0,58%
13	Jan Lundberg	3000000	0,56%
14	Handelsbanken Fonder	2741217	0,51%
15	Håkan Svanberg	2709200	0,50%
16	Lars Widell	2694608	0,50%
17	Skandia Fonder	2404114	0,45%
18	Carl Michael Augustsson	2402390	0,45%
19	Chirp AB	2095129	0,39%
20	Kent Olsson	2082861	0,39%
			45,12%